SOURCE: UV Flu Technologies, Inc.

UV Flu Technologies, Inc.

August 18, 2010 09:00 ET

UV Flu Technologies Plans National Television Sales Awareness Campaign

CENTERVILLE, MA--(Marketwire - August 18, 2010) -  UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that it has signed an agreement with Trade Network, Inc., dba Creative Media and Buying Services, to produce a series of television advertisements in order to publicize a national awareness campaign featuring the ViraTech UV-400 product line, and its proven health benefits in relationship to the ongoing and growing dangers presented by poor indoor air quality in homes, and workplaces across the nation.

The commercials are slated to air beginning in October, just prior to the onset of the traditional flu season, and will be broadcast on a variety of national television networks at various airtimes. They will be broadcast throughout this heightened period of awareness and, as such, are designed to offer an informative and educational outlook demonstrating the design and proven effectiveness of the UV-400 bacteria killing air purifier in action.

The indoor air quality ("IAQ") sector is a vast market that grows in significance every time an airborne illness penetrates public mainstream awareness. This generally occurs in the fall and spring seasons and is usually in the forefront of public awareness during the fall season when the Company's advertisements are scheduled for broadcast.

"This campaign is expected to not only to raise national awareness of the ViraTech UV-400 and its ability to kill bacteria and other contaminants, but to also spotlight the epidemic increase in respiratory problems due to poor indoor air quality generally," stated Jack Lennon, President of UV Flu Technologies. "These television spots are an integral part of our overall marketing plan intended to capture a significant percentage of the worldwide multibillion dollar air-purification and filtration product marketplace, by demonstrating a product that actually works, and which has been cleared by the FDA as a medical device specifically for killing bacteria. The UV-400 product, along with several other products currently under development is directly aimed at reducing the extraordinary number of deaths attributed to poor indoor air quality that occur around the world every year."

The UV-400 is uniquely positioned to attract serious attention by consumers due to its listing as a Medical Device with the FDA which resulted after a battery of rigorous laboratory tests proved the UV-400 kills 99% of airborne bacteria in its patented UV chamber. The device is designed to easily circulate the air within the average home or work environment multiple times per hour, and will be demonstrated within a number of real life situations and applications throughout the television presentations.

Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.


UV Flu Technologies, Inc.
John J. Lennon, President & CEO

Contact Information

  • Investor Information:
    Geaux IR Services, Inc.
    Toll-Free: 1-888-355-8838
    Email Contact